Bluefin Achieves Girocard Certification for the Newland Payment Technology N950 AIO smartPOS
Bluefin has achieved the German Banking Industry Committee’s (GBIC German: Deutsche Kreditwirtschaft) Girocard certification on the Newland NPT N950 AIO smartPOS terminal. This certification enables German merchants to adopt next-generation SmartPOS devices while simplifying Girocard payment acceptance through Bluefin’s TECS Engine, a global payments platform.
Bluefin’s TECS Engine provides omnichannel payment solutions to Acquirers, Payment Service Providers, POS system providers, Independent Software Vendors (ISVs) and other merchant aggregators around the globe offering a cloud-based Payments Platform-as-a-Service, including Bluefin’s payment and data security solutions, P2PE and universal tokenization.
As the leading debit card in Germany, Girocard conducted 7.5 billion transactions in 2023. With Girocard certification on the Newland N950 AIO smartPOS terminal, the German market will benefit from an open platform with access to new generations of SmartPOS devices and streamlined Girocard payment acceptance while benefitting from lower merchant service fees.
“Achieving Girocard certification for the Newland N950 AIO smartPOS is a key milestone for TECS and Bluefin, reinforcing our commitment to delivering secure, innovative, and globally adaptable payment solutions,” said Anton Scheiber, International Sales & Business Development Director, Bluefin. “This certification provides new opportunities for merchants in Germany, giving them access to innovative SmartPOS technology while ensuring seamless Girocard payment acceptance.”
The Newland N950 is an Android SmartPOS terminal designed for seamless and secure payments across industries like retail, hospitality, and dining. Featuring a sleek touchscreen display and support for multiple payment methods – including chip and PIN, contactless, NFC, and QR-code payments – the N950 enhances customer engagement while streamlining transactions.
“We are excited to partner with Bluefin to bring the Newland N950 to the German market with Girocard certification,” said Kazem Aminaee, International President at Newland Payment Technology. “As a next-generation SmartPOS solution, the N950 combines advanced payment technology with a flexible platform, empowering businesses to enhance their payment experience while supporting Germany’s leading domestic debit card.”
About Bluefin
Bluefin is the recognized integrated payments leader in encryption and tokenization technologies that protect payments and sensitive data. Our product suite includes solutions for contactless, face-to-face, call center, mobile, E-commerce and unattended payments and data in the healthcare, higher education, government and nonprofit industries. The company’s 300 global partners serve 35,000 connected enterprise and software clients operating in 60 countries. Bluefin is a Participating Organization (PO) of the PCI Security Standards Council (SSC) and is headquartered in Atlanta, with offices in Waterford, Ireland and Vienna, Austria. For more information, visit https://www.bluefin.com/.
About Newland NPT
Newland NPT (Newland Payment Technology) is a leading global provider of payment acceptance technology. With over 30 years’ experience supplying best-in-class solutions, and working with partners in over 120 countries, Newland has successfully deployed over 100 million payment devices worldwide. For more information, visit https://www.newlandnpt.com/.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250218500456/en/
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Compass Pathways Announces FDA Acceptance of IND Application for PTSD and Hosts Webinar on PTSD and TRD7.1.2026 12:30:00 CET | Press release
FDA Accepts Investigational New Drug (IND) Application for COMP360 for the treatment of post-traumatic stress disorder (PTSD), enabling initiation of late-stage trialCompass continues to advance commercial preparations to be launch-ready by the end of the year for COMP360 for treatment-resistant depression (TRD)Management will host webinar with KOL and industry leaders to discuss PTSD clinical trial and commercial preparations for TRD from 10:00-11:30 am ET on January 7th Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation, today announced that the U.S. Food and Drug Administration (FDA) has accepted its Investigational New Drug (IND) application for COMP360, enabling the initiation of a late-stage clinical trial in patients with PTSD. Compass management, along with KOL and industry leaders, will host a webinar today to discuss the company’s clinical trial plans for PTSD, as well as commercial preparations f
Stallergenes Greer Expands Venom Immunotherapy Production Capacity With Acquisition of Entomon s.r.l.7.1.2026 11:07:00 CET | Press release
Stallergenes Greer, a global leader in allergy therapeutics, today announced that it has entered into an agreement to acquire Entomon s.r.l., an Italian company specialising in the production of certified stinging-insect venom extracts, notably of the Hymenoptera order, used for the manufacture of diagnostic preparations and Venom Immunotherapy (VIT). The transaction is expected to close by the end of January. Entomon, currently recognised as the only company in Europe capable of extracting pure venom from Hymenoptera insects, produces pharmaceutical-grade insect venom using proprietary techniques (Entomon Capillary Extracted Venom®) for medical use. Through this acquisition, Stallergenes Greer bolsters its venom manufacturing capabilities and supply of raw materials for life-saving VIT treatments, whilst safeguarding patient care continuity. Hymenoptera venom allergy is the most common trigger of severe anaphylaxis in adults1. According to the EAACI guidelines on venom immunotherapy,
ARIS Announces New CEO to Lead Agentic AI-led Strategy7.1.2026 10:00:00 CET | Press release
CEO Appointment ARIS, a global leader in process intelligence and transformation software, today announced the appointment of Guillaume Bacuvier as Chief Executive Officer. Guillaume will lead ARIS through its next phase of growth as a fully standalone company, accelerating its evolution from a market leader in Process Intelligence into a foundational platform for enterprises deploying and governing Agentic AI. Guillaume brings deep international leadership experience across technology, data, and software-enabled businesses, with a proven track record of scaling global platforms and leading complex organisations. After starting as a strategic consultant at Booz Allen Hamilton, Guillaume spent over a decade at Google, rising to Vice President in EMEA where he built and scaled some of Google’s largest data-driven businesses in Europe and held P&L responsibility across multiple countries. In the last decade, Guillaume has served as CEO of multi-continent, data-centric companies including
I Squared Capital Acquires Ramudden Global, a Leader in Traffic Management and Infrastructure Safety7.1.2026 09:00:00 CET | Press release
Acquisition will accelerate Ramudden’s ambitious growth plan across North America and Europe supported by strong infrastructure spending tailwinds I Squared Capital, a leading global infrastructure investment manager, today announced that, through its flagship fund, it has agreed to acquire Ramudden Global, from funds advised by Triton Partners (“Triton”), a leading European mid-market sector-specialist investor. Ramudden Global is a leading international provider of traffic management and infrastructure safety services supporting the maintenance and upgrade of essential transport and utility networks. The company operates more than 190 depots across 13 countries in Europe and North America delivering mission-critical services that help to ensure safety, regulatory compliance and continuity of service across road, utility and broader infrastructure works. This investment underscores I Squared Capital’s commitment to investing in essential, regulated, infrastructure businesses that unde
RoslinCT and BOOST Pharma Announce Strategic Manufacturing Agreement to Advance Cell Therapy for Infants with Osteogenesis Imperfecta7.1.2026 09:00:00 CET | Press release
RoslinCT, a global contract development and manufacturing organization (CDMO) specializing in advanced cell therapies, and BOOST Pharma, a clinical-stage biotechnology company developing first-in-class cell therapies for rare paediatric skeletal diseases, today announced a strategic manufacturing partnership to support the development of BOOST Pharma’s cell therapy, BT-101, for the treatment of infants with Osteogenesis Imperfecta (OI), also known as brittle bone disease. Under the service agreement, BOOST Pharma has transferred its manufacturing process to RoslinCT’s state-of-the-art facilities in Edinburgh, Scotland. The partnership will progress toward GMP manufacturing of starting materials and clinical drug product, supporting Phase III clinical development of BT-101. The therapy is an allogeneic mesenchymal stem cell (MSC) product designed to address the underlying cause of OI at the earliest stages of life. BOOST Pharma was founded on pioneering science originating from Karolins
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom